To access all features of this site, you must enable Javascript. Here are the instructions for enabling Javascript in your web browser.
The François Jacob Institute of Biology brings together five departments and three services
The last two years in scientific news
In a study published in Nature Communications, IDMIT researchers demonstrated the efficacy of a neutralizing antibody against cell-associated infection by simian-human immunodeficiency virus.
Using a murine preclinical model wherein Rad51 was selectively inhibited, researchers from the Laboratory of Development of the Gonads (iRCM:CEA-Jacob) and the Institut Cochin showed that in vivo alteration of Rad51-mediated homologous recombination does not favor the development of cancers, it reduces it. The team's work was published in The Embo Journal.
In an article published in Nature Communications, researchers from Institut Jacques-Monod and iRCM (CEA-Jacob) merged imaging and biochemistry approaches to show that the genes involved in expression are conducted to nuclear pores in order to protect the genome.
In an article published in Science of The Total Environment, researchers from the Genomics Metabolics mixed research unit (Genoscope/CEA-Jacob) teamed with colleagues from the University of Lorraine to demonstrate the role of thermophilic anaerobic digestion in the biodegradation of chlordecone.
In a new study published in Nature Communications, researchers from IDMIT and the QIMR Berghofer Institute have shown that a peptide able to inhibit the nuclear ACE2 receptor provides protection against SARS-CoV-2 infection.
In a study published in Heliyon, researchers from IDMIT (CEA-Jacob) used a well-characterized non-human primate model to show that sotrovimab is efficacious against the BQ.1.1 subvariant of SARS-CoV-2. Their results lend support for the continued use of sotrovimab in patients ineligible for nirmatrelvir/ritonavir.
In a new study performed in a mouse model and published in Acta Neuropathologica Communications, researchers from the LMN (MIRCen/CEA-Jacob) have shown that the experimental transmission of abnormal amyloid-β proteins accelerates, over time, the development of cerebral lesions and memory disorders.
In an article published in Neurobiology of Disease, researchers from MIRCen's Neurodegenerative Diseases Laboratory present a novel model of Alzheimer's disease that enables the study of tauopathy inter-neuronal propagation mechanisms, the identification of new therapeutic targets and the exploration of new treatments.
Top page
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.